Reported earlier, Knight Therapeutics Sees FY2026 Sales $490.000M-$510.000M vs $465.827M Est

Benzinga Newsdesk www.benzinga.com Positive 75.9%

Neg 0% Neu 0% Pos 75.9%

Knight Therapeutics (TSX:GUD) sees FY2026 sales of $490.000 million-$510.000 million vs $465.827 million analyst estimate.